RESTORING A HEALTHY EXTRACELLULAR MATRIX CAN RE-SENSITIZE CANCER
TO ONCOLOGIC THERAPIES AND RESTORE TISSUE AND ORGAN FUNCTION

ALENTIS’ UNIQUE CLDN1 MONOCLONAL ANTIBODIES
CAN REVERT THE EXTRACELLULAR MATRIX TO ITS
HEALTHY STATE IN CANCERS AND ORGAN TISSUES

Alentis is developing a portfolio of first-in-class anti-CLDN1 monoclonal antibodies (mAbs) that bind to CLDN1 exposed outside of the tight junction to treat cancers and fibrotic diseases

ALE.C04

CLDN1 mAb has been designed with an effector function directly targeting cancer while silencing CLDN1-mediated carcinogenic signaling and opening up the stiff extracellular matrix (ECM) in tumors with immune evasive properties. IND-enabling studies are currently ongoing with a Phase 1/2 first-in-human clinical trial planned to start during the second half of 2023.

ALE.F02

CLDN1 mAb has been designed with a silenced effector function to target the stiff ECM of fibrotic tissues and organs and is currently under development for kidney, lung, and liver fibrosis. ALE.F02’s translational data predict robust efficacy and safety across multiple organ fibrosis indications. Topline data from a Phase 1 clinical trial in healthy volunteers were reported in 2023, several other clinical trials are planned to start during 2023.

Next Generation: Alentis CLDN1 Technology (ACT) Platform

The Next Generation CLDN1 Platform is under development for an enhanced mechanism of action in several indications to expand approaches for ECM restoration and to develop and potentiate the efficacy of cancer treatments. Among others Alentis is exploring antibody drug conjugates (ADCs) and potential other payloads and approaches.